Latest News
Conference Coverage
Most dermatologic drugs safe for breastfeeding mothers
CHICAGO – Despite many physicians’ concerns, most dermatology drugs do not pose risks to the nursing infant or to...
Conference Coverage
IL inhibitor options move psoriasis treatment forward
Long-term data continue to support the safety and effectiveness of IL-17 and IL-23 inhibitor drugs.
News
Adalimumab safety update finds no new signals
The new integrated analysis includes safety data from five clinical trials that were not included in the analysis from 2009.
Conference Coverage
Anti-TNF agents preferred for severe psoriasis in pregnancy
CHICAGO – Safety data supports anti-TNF agents first for systemic treatment of severe psoriasis in pregnancy,...
News
Adalimumab safety profile similar in children and adults
The most common adverse events across indications were upper respiratory tract infection, nasopharyngitis, and headache.
News
No evidence of subclinical axial involvement seen in skin psoriasis
Patients with longstanding psoriasis without peripheral or axial inflammation are unlikely to have subclinical involvement of the sacroiliac joint...
Latest News
Novel oral agent shows unprecedented efficacy in psoriasis
PARIS – Selective tyrosine kinase 2 inhibitor reached a 75% PASI 75 response rate in moderate to severe psoriasis at 12 weeks.
News
Elevated type 2 diabetes risk seen in PsA patients
Type 2 diabetes risk was significantly higher among patients with psoriatic arthritis, even when compared with patients with psoriasis alone.
News
Infliximab biosimilar only moderately less expensive in Medicare Part D
Without biosimilar gap discounts in 2017, beneficiaries would have paid nearly $1,700 more in projected out-of-pocket costs for infliximab-dyyb...
News
Risankizumab proves more effective in psoriasis than ustekinumab
Two phase 3 trials suggested that risankizumab can do more to improve quality of life, with similar safety.